Omnix Medical Announces First Patient Dosed in Phase II Trial of Antimicrobial Lead Compound OMN6
— Novel mechanism of action based on the direct physical elimination of pathogenic bacteria — First-in-class treatment of life-threatening, drug-resistant Acinetobacter baumannii infections advancing toward Phase II clinical proof-of-concept JERUSALEM, Israel, May, 2026 — Omnix Medical, a biopharmaceutical company developing next-generation anti-infectives for severe multidrug-resistant infections, announced today that the first patient in a Phase […]